What does US7803839B2 cover for cobimetinib (Exelixis)?
US7803839B2 is a US patent in the Exelixis family that relates to cobimetinib (also known by the development code GDC-0973), focusing on chemical synthesis aspects—specifically how the compound (and related intermediates) can be prepared. The patent is categorized as a “composition/synthesis” style patent, meaning it is aimed at manufacturing steps and/or synthetic routes that lead to cobimetinib rather than only on downstream medical use.
Why do people look up US7803839B2 in cobimetinib patent searches?
Patent searches often target manufacturing/synthesis patents because they can affect:
- who can make cobimetinib for supply or development purposes,
- what “process” changes might avoid infringement (a different synthetic route can sometimes fall outside claim scope),
- and how freedom-to-operate timelines line up with other patents tied to the same drug.
Synthesis patents can be especially relevant when evaluating generic or alternative-manufacturing strategies, even when the final product is the same.
How to find the exact claim language for “exelixis cobimetinib synthesis” in US7803839B2
To match your use case (e.g., process design, legal/FTO review, or a research synthesis plan), you generally need to review:
- independent claims (often the broadest synthetic process claims),
- dependent claims (which add constraints like specific reagents, conditions, temperatures, solvents, or purification steps),
- and any listed intermediates (because claim coverage can hinge on whether you synthesize those intermediates in a particular way).
If you share what you’re trying to do (freedom-to-operate, replicating a route, or mapping the patent landscape), I can point you to the most relevant claim sections to look at.
Does US7803839B2 affect ability to make cobimetinib today?
Synthesis patents can still matter after other drug patents expire, depending on:
- whether the US application issued as US7803839B2 and remains in force,
- whether the patent term was adjusted (for patent term adjustments) and whether any terminal disclaimers apply,
- and whether there are later patents that cover the same manufacturing steps or intermediates.
To determine practical impact, you typically cross-check:
- the patent’s maintenance status,
- its current legal status/expiration date,
- and overlap with other cobimetinib patents in the same family.
Where to check patent and status details quickly
For consolidated patent listings and related cobimetinib entries, DrugPatentWatch.com can be useful:
- https://drugpatentwatch.com/ (search for cobimetinib / Exelixis and the patent number US7803839B2)
What I need from you to give a precise, claim-level answer
Right now, I don’t have the specific text of US7803839B2 claims in your prompt. If you paste:
- the abstract, or
- claim 1 (and any dependent claims you care about), or
- a link to the Google Patents/EPO record you’re using,
I can summarize exactly what synthetic steps or intermediates the patent claims for cobimetinib, and highlight what parts are most likely to be legally sensitive.
Sources
- https://drugpatentwatch.com/